Cargando…

Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation

OBJECTIVES: Since the introduction of the German health care reform in January 2011, an early benefit assessment (EBA) is required for all new medicines. Pharmaceutical manufacturers have to submit a benefit dossier for evaluation by the Institute for Quality and Efficiency in Health Care (IQWiG). A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruof, Jörg, Schwartz, Friedrich Wilhelm, Schulenburg, J.-Matthias, Dintsios, Charalabos-Markos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2013
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059963/ https://www.ncbi.nlm.nih.gov/pubmed/23771769 http://dx.doi.org/10.1007/s10198-013-0495-y

Ejemplares similares

“Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations
por: Staab, Thomas R., et al.
Publicado: (2018)

How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?
por: Dintsios, Charalabos-Markos, et al.
Publicado: (2021)

Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany – are additional data requirements by the Federal Joint Committee justified?
por: Ruof, Jörg, et al.
Publicado: (2016)

Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany
por: Dabisch, Inna, et al.
Publicado: (2014)

Predictors of negotiated prices for new drugs in Germany
por: Gandjour, Afschin, et al.
Publicado: (2020)

10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
por: Büssgen, Melanie, et al.
Publicado: (2023)

Implementation of AMNOG: An industry perspective
por: Leverkus, Friedhelm, et al.
Publicado: (2015)

Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment
por: Gandjour, Afschin
Publicado: (2023)

The impact of HTA reports on health policy: a systematic review
por: Gerhardus, Ansgar, et al.
Publicado: (2005)

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree
por: Dintsios, C. M., et al.
Publicado: (2019)

Promoting physical activity in low back pain patients: six months follow-up of a randomised controlled trial comparing a multicomponent intervention with a low intensity intervention
por: Schaller, Andrea, et al.
Publicado: (2016)

Coated stents to prevent restenosis in coronary heart disease
por: Gorenoi, Vitali, et al.
Publicado: (2005)

Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
por: Ruof, Jörg, et al.
Publicado: (2015)

Quantified patient preferences for lifestyle intervention programs for diabetes prevention—a protocol for a systematic review
por: Dintsios, Charalabos-Markos, et al.
Publicado: (2018)

Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease
por: Gorenoi, Vitali, et al.
Publicado: (2008)

Intravascular brachytherapy for peripheral vascular disease
por: Gorenoi, Vitali, et al.
Publicado: (2008)

Laparoscopic vs. open appendectomy: systematic review of medical efficacy and health economic analysis
por: Gorenoi, Vitali, et al.
Publicado: (2007)

Real world data in health technology assessments in kidney transplants in Germany: use of routinely collected data to address epidemiologic questions in kidney transplants in the AMNOG process in Germany
por: Herrmann, Kirsten H., et al.
Publicado: (2018)

Relevance of Variations in the Opposing Dentition for the Functionality of Fixed and Removable Partial Dentures: A Systematic Review
por: Pommer, Bernhard, et al.
Publicado: (2012)

Ten years of AMNOG from an oncological perspective: new horizons and continuing expansion
por: Bartol, Arne, et al.
Publicado: (2022)

The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany
por: Dintsios, C. M., et al.
Publicado: (2020)

Benefit assessment in Germany: implications for price discounts
por: Theidel, Ulrike, et al.
Publicado: (2016)

Krebsforschung in Deutschland zwischen AMNOG, CTIS und digitalen Datenräumen: An der Schnittstelle zur Zukunft
por: Grätzel von Grätz, Philipp
Publicado: (2023)

External validation of type 2 diabetes computer simulation models: definitions, approaches, implications and room for improvement—a protocol for a systematic review
por: Ogurtsova, Katherine, et al.
Publicado: (2017)

Zehn Jahre AMNOG-Prozess aus Sicht der Onkologie: Neuland erschlossen, Bebauung geht weiter
por: Bartol, Arne, et al.
Publicado: (2022)

Development and validation of the Exteroceptive Body Awareness (EBA-q) questionnaire
por: Vabba, Alisha, et al.
Publicado: (2023)

Effect of Insurance Legislation on National Character in Germany
Publicado: (1913)

Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis
por: Wallis, Robert S., et al.
Publicado: (2014)

Preliminary experience with EBA ONE intramedullary nail for the treatment of pertrochanteric fractures
por: Oldani, Danila, et al.
Publicado: (2019)

The european paediatric legislation: benefits and perspectives
por: Rocchi, Francesca, et al.
Publicado: (2010)

Effect of Smoke-Free Legislation on Adult Smoking Behaviour in England in the 18 Months following Implementation
por: Lee, John Tayu, et al.
Publicado: (2011)

Implementation of a multicomponent intervention to prevent physical restraints in nursing home residents (IMPRINT): study protocol for a cluster-randomised controlled trial
por: Abraham, Jens, et al.
Publicado: (2015)

Perspektiven der molekulargenetischen Therapien: Zur Notwendigkeit der Weiterentwicklung des AMNOG Bewertungssystems im Bereich der personalisierten Medizin
por: Woskowski, Silvia, et al.
Publicado: (2022)

Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany
por: Kuhlmann, Alexander, et al.
Publicado: (2012)

Development, validation and clinical use of the Eating Behaviors Assessment for Obesity (EBA-O)
por: Segura-Garcia, Cristina, et al.
Publicado: (2022)

Patient-reported data informing early benefit assessment of rare diseases in Germany: A systematic review
por: Babac, Ana, et al.
Publicado: (2019)

The cytoplasmic domain of the Plasmodium falciparum ligand EBA-175 is essential for invasion but not protein trafficking
por: Gilberger, Tim-Wolf, et al.
Publicado: (2003)

Genetic evidence for contribution of human dispersal to the genetic diversity of EBA-175 in Plasmodium falciparum
por: Yasukochi, Yoshiki, et al.
Publicado: (2015)

Proprioceptive drift in the rubber hand illusion is intensified following 1 Hz TMS of the left EBA
por: Wold, Andrew, et al.
Publicado: (2014)

Structural and Functional Basis for Inhibition of Erythrocyte Invasion by Antibodies that Target Plasmodium falciparum EBA-175
por: Chen, Edwin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_o60fbntpgcr3f3a7cmkm1akqi0